Volume 46, Issue 3, Pages (March 2017)

Slides:



Advertisements
Similar presentations
Volume 43, Issue 6, Pages (December 2015)
Advertisements

Volume 25, Issue 6, Pages (December 2006)
Volume 31, Issue 1, Pages (July 2009)
Volume 21, Issue 2, Pages e5 (August 2017)
Functional Analysis of Glycosylation of Zika Virus Envelope Protein
David X Liu, Lloyd A Greene  Neuron 
Volume 41, Issue 6, Pages (December 2014)
Maternal-Derived Hepatitis B Virus e Antigen Alters Macrophage Function in Offspring to Drive Viral Persistence after Vertical Transmission  Yongjun Tian,
Volume 46, Issue 6, Pages e5 (June 2017)
Volume 21, Issue 11, Pages (December 2017)
Volume 11, Issue 6, Pages (June 2012)
Volume 40, Issue 3, Pages (March 2014)
Volume 5, Issue 6, Pages (December 2015)
Volume 22, Issue 1, Pages e4 (July 2017)
Activation of the Innate Signaling Molecule MAVS by Bunyavirus Infection Upregulates the Adaptor Protein SARM1, Leading to Neuronal Death  Piyali Mukherjee,
Volume 38, Issue 1, Pages (January 2013)
Volume 23, Issue 5, Pages (May 2018)
Volume 20, Issue 5, Pages (November 2016)
Brian Yordy, Norifumi Iijima, Anita Huttner, David Leib, Akiko Iwasaki 
Volume 36, Issue 3, Pages (March 2012)
Volume 18, Issue 11, Pages (November 2011)
Volume 8, Issue 6, Pages (December 2010)
Volume 18, Issue 13, Pages (March 2017)
A Mouse Model of Zika Virus Pathogenesis
Volume 23, Issue 10, Pages (October 2015)
Alex M. Agelidis, Satvik R. Hadigal, Dinesh Jaishankar, Deepak Shukla 
Volume 5, Issue 3, Pages (March 2009)
TAM Receptors Are Not Required for Zika Virus Infection in Mice
Volume 20, Issue 5, Pages (November 2016)
Hemagglutinin-targeting Artificial MicroRNAs Expressed by Adenovirus Protect Mice From Different Clades of H5N1 Infection  Xinying Tang, Hongbo Zhang,
Jungmook Lyu, Vicky Yamamoto, Wange Lu  Developmental Cell 
Volume 21, Issue 6, Pages (November 2017)
Modified mRNA Vaccines Protect against Zika Virus Infection
Volume 40, Issue 1, Pages (January 2014)
Zika Virus Targets Human STAT2 to Inhibit Type I Interferon Signaling
Volume 12, Issue 1, Pages (July 2015)
miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK
TET3 Inhibits Type I IFN Production Independent of DNA Demethylation
Volume 19, Issue 2, Pages (August 2016)
Incorporation of the B18R Gene of Vaccinia Virus Into an Oncolytic Herpes Simplex Virus Improves Antitumor Activity  Xinping Fu, Armando Rivera, Lihua.
Volume 3, Issue 1, Pages (July 2014)
Glycogen Synthase Kinase 3β Regulates IRF3 Transcription Factor-Mediated Antiviral Response via Activation of the Kinase TBK1  Cao-Qi Lei, Bo Zhong, Yu.
C-Jun Downregulation by HDAC3-Dependent Transcriptional Repression Promotes Osmotic Stress-Induced Cell Apoptosis  Yan Xia, Ji Wang, Ta-Jen Liu, W.K.
Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models  Fabrice Le Boeuf, Simon Gebremeskel,
Volume 48, Issue 4, Pages e4 (April 2018)
High-Throughput Fitness Profiling of Zika Virus E Protein Reveals Different Roles for Glycosylation during Infection of Mammalian and Mosquito Cells 
Volume 6, Issue 1, Pages (July 2009)
Volume 30, Issue 3, Pages (March 2009)
Volume 16, Issue 3, Pages (September 2014)
GRM7 Regulates Embryonic Neurogenesis via CREB and YAP
Xuepei Lei, Jianwei Jiao  Stem Cell Reports 
Volume 20, Issue 4, Pages (October 2016)
Lukxmi Balathasan, Vera A
Volume 20, Issue 5, Pages (November 2016)
Volume 5, Issue 5, Pages (May 2009)
Volume 21, Issue 6, Pages (November 2017)
Modeling Dengue Virus-Hepatic Cell Interactions Using Human Pluripotent Stem Cell- Derived Hepatocyte-like Cells  Jianshe Lang, Daniel Vera, Yichen Cheng,
Volume 40, Issue 4, Pages (April 2014)
Volume 40, Issue 4, Pages (April 2014)
Molecular Therapy - Nucleic Acids
Volume 40, Issue 3, Pages (March 2014)
Molecular Therapy - Oncolytics
Volume 31, Issue 6, Pages (December 2009)
Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Δ4 with a Set of Gene Deletions on Several Viral Pathways  Ernesto Mejías-Pérez,
A Direct HDAC4-MAP Kinase Crosstalk Activates Muscle Atrophy Program
Volume 13, Issue 11, Pages (December 2015)
Volume 38, Issue 3, Pages (March 2013)
Volume 21, Issue 1, Pages (January 2017)
Volume 20, Issue 2, Pages (August 2016)
Volume 11, Issue 6, Pages (June 2012)
Presentation transcript:

Volume 46, Issue 3, Pages 446-456 (March 2017) 25-Hydroxycholesterol Protects Host against Zika Virus Infection and Its Associated Microcephaly in a Mouse Model  Chunfeng Li, Yong-Qiang Deng, Shuo Wang, Feng Ma, Roghiyh Aliyari, Xing-Yao Huang, Na-Na Zhang, Momoko Watanabe, Hao-Long Dong, Ping Liu, Xiao-Feng Li, Qing Ye, Min Tian, Shuai Hong, Junwan Fan, Hui Zhao, Lili Li, Neda Vishlaghi, Jessie E. Buth, Connie Au, Ying Liu, Ning Lu, Peishuang Du, F. Xiao-Feng Qin, Bo Zhang, Danyang Gong, Xinghong Dai, Ren Sun, Bennett G. Novitch, Zhiheng Xu, Cheng-Feng Qin, Genhong Cheng  Immunity  Volume 46, Issue 3, Pages 446-456 (March 2017) DOI: 10.1016/j.immuni.2017.02.012 Copyright © 2017 Terms and Conditions

Immunity 2017 46, 446-456DOI: (10.1016/j.immuni.2017.02.012) Copyright © 2017 Terms and Conditions

Figure 1 ZIKV-Triggered Induction of CH25H Plays an Important Role in Host Anti-ZIKV Immunity (A) A549 cells were infected with ZIKV (GZ01/2016 strain, MOI 5) for 24 hr, RNA-seq was performed, and the top 50 genes upregulated by ZIKV infection in A549 cells were shown. (B) A549 cells were infected with indicated MOI of ZIKV (GZ01/2016 strain) for 24 hr, CH25H mRNA expression was measured by qRT-PCR. (C and D) WT and CH25H−/− A549 cells were infected with ZIKV (GZ01/2016 strain, MOI 0.1) for 48 hr, ZIKV in cell lysates, and the supernatant was measured by qRT-PCR (C) and plaque assay (D), respectively. (E) HeLa cells were transfected with plasmids expressing GFP, IRF1, CH25H, or CH25H-M (hydroxylase activity-dead mutant) for 24 hr, followed by infecting cells with ZIKV (GZ01/2016 strain) for 48 hr at MOI of 0.1. The titer of ZIKV in the supernatant was quantified by plaque assay. (F) BHK-21 cells were treated with conditioned media from HeLa cells expressing the indicated genes for 12 hr and infected with ZIKV (GZ01/2016 strain, 200PFU). Then, the BHK-21 cells were subjected to plaque assay. Data of (B)–(F) are shown as mean ± SEM from three independent experiments. ∗p ≤ 0.05, ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001, unpaired Student’s t test. See also Figure S1–S3. Immunity 2017 46, 446-456DOI: (10.1016/j.immuni.2017.02.012) Copyright © 2017 Terms and Conditions

Figure 2 25HC Broadly Inhibits Flaviviruses Infection (A and B) Vero cells were pretreated with EtOH or indicated dose of 25HC for 8 hr, followed by ZIKV infection (GZ01/2016 strain, MOI 0.1). The titer of ZIKV in the supernatant was quantified by (A) plaque assay and (B) qRT-PCR. (C–F) Vero cells were pretreated with indicated amount of 25HC for 8 hr and then infected with (C) ZIKV GZ01/2016 strain, (D) DENV, (E) YFV, and (F) WNV at MOI 0.1. Viral RNA copies in cell lysates were quantified by qRT-PCR. IC50 of 25HC to ZIKV, DENV, YFV, and WNV were calculated and indicated. All data are shown as mean ± SEM from three independent experiments. ∗∗p ≤ 0.01, unpaired Student’s t test. See also Figure S4. Immunity 2017 46, 446-456DOI: (10.1016/j.immuni.2017.02.012) Copyright © 2017 Terms and Conditions

Figure 3 25HC Suppressed ZIKV Infection by Blocking Viral Entry (A) BHK-21 cells were treated with EtOH, 1 and 5 μM 25HC, and NITD008 for 12 hr, followed by infecting cells with ZIKV (GZ01/2016 strain, 200 PFU/well) at 4°C for 1 hr. Cells were washed with cold PBS and incubated at 37°C for 1 hr. The titer of internalized virus was measured with plaque assay. (B) C6/36 cells were infected with DENV (MOI 0.2) for 4 days and treated with 25HC for another 8 hr. Syncythia formation was stimulated with medium (pH 5.8) for 2 hr and then replaced with fresh regular medium. 24 hr post stimulation, C6/36 cells were stained with Giemsa. 4G2 and NITD008 were used as positive and negative controls, respectively. Syncythias were defined as the cells containing four or more nuclei. The number of syncythias in samples with EtOH was set to 100%. (C) A549 cells were pretreated with indicated concentration of Liposome, and 25HC or EtOH, for 8 hr. Cells were infected with ZIKV (GZ01/2016 strain, MOI 0.3) in 37°C, followed by plaque assay at 48 hpi. (D) BHK-21 cells were transfected with RNA from ZIKV/DENV replicon. 6 hr post transfection, 25HC was added into cells, and subsequently, renilla luciferase activity in cell lysates was determined at 48 hr post transfection. NITD008 was used as positive control. All data are shown as mean ± SEM from three independent experiments, ∗p ≤ 0.05, ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001, unpaired Student’s t test. See also Figure S5. Immunity 2017 46, 446-456DOI: (10.1016/j.immuni.2017.02.012) Copyright © 2017 Terms and Conditions

Figure 4 25HC Reduces ZIKV Viremia and Improves Survival in Mice (A) 3- to 4 week-old female BALB/c mice were injected i.p. with 25HC (50 mg/kg) or vehicle HβCD for 12 hr and subjected to ZIKV infection i.p. (1 × 105 PFU GZ01/2016 strain). The viral copy number in serum was quantified by qRT-PCR at 1 dpi. Vehicle: n = 6; 25HC: n = 9. (B–E) 3- to 4-week-old female A129 mice were pretreated with 25HC or vehicle as described in (A) and 12 hr later were infected i.p. with 2 × 105 PFU (B) or 2 × 103 PFU (C-E) ZIKV (GZ01/2016 strain). 25HC or vehicle were administrated daily for seven days. (B) The rate of mice survival until 21 dpi and (C) the level of ZIKV RNA in serum at 4 dpi (D) and 7 dpi (E) and in the brain were measured by qRT-PCR. Log-Rank (Mantel-Cox) test were used in (B), vehicle: n = 6; 25HC: n = 8 ∗p ≤ 0.05. Median value of (A, C–E) has been shown, vehicle: n = 7; 25HC: n = 8 (C and D); vehicle/25HC: n = 5 (E). ∗p ≤ 0.05, ∗∗p ≤ 0.01, unpaired Student’s t test. Immunity 2017 46, 446-456DOI: (10.1016/j.immuni.2017.02.012) Copyright © 2017 Terms and Conditions

Figure 5 25HC Protects Rhesus Monkeys from ZIKV Infection (A and B) Rhesus monkeys were injected i.v. with 25HC (1.5 mg/kg) (n = 2) or the vehicle control EtOH (n = 3), followed by infection with 1x103 PFU of ZIKV (GZ01/2016 strain) i.m. Animals were treated with 25HC or EtOH daily for 7 days. Viral copy numbers in (A) serum and (B) urine of control monkeys or 25HC-pretreated were measured by qRT-PCR. (C) The level of IFN-γ, IL-15, and CXCL9 in the serum of infected animals was measured at 0, 3, and 7 dpi by Luminex assay. Data of (C) are shown as mean ± SD from three experimental replicates, ∗p ≤ 0.05, ∗∗p ≤ 0.01, unpaired Student’s t test. See also Figure S6. Immunity 2017 46, 446-456DOI: (10.1016/j.immuni.2017.02.012) Copyright © 2017 Terms and Conditions

Figure 6 25HC Inhibits ZIKV Infection in Human Cortical Organoids Human cortical organoids were differentiated from hES. On day 20, these organoids were inoculated with ZIKV (PRVABC59/2015 strain, MOI 1). (A–C) Organoids were inoculated with ZIKV for indicated time, and expression of ZIKV genomic RNA (A), IFNB (B), and CH25H (C) was quantified by qRT-PCR. (D–F) Human cortical organoids were pretreated with indicated dose of 25HC or EtOH for 15 hr and then infected with ZIKV for 48 hr. ZIKV genomic RNA and titer were quantified by (D) qRT-PCR or (E) plaque assay. (F) Left: ZIKV E protein in these organoids was stained by immunofluorescence assay. Right: ZIKV+ cells were also quantified. Green: ZIKV E protein; blue: HOECHST; red: CTIP2. Scale bars; left, 500 μm; right, 100 μm. Data of (A–E) are shown as mean ± SEM from three independent experiments, ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001, unpaired Student’s t test. Data of (F) are representative of three independent experiments. Immunity 2017 46, 446-456DOI: (10.1016/j.immuni.2017.02.012) Copyright © 2017 Terms and Conditions

Figure 7 25HC Protects the Embryonic Brains from ZIKV-Induced Microcephaly Embryonic brains were injected with ZIKV (SZ01/2016, 650 PFU/brain) or medium at E13.5 and inspected at E18.5 with or without treatment with 25HC (50 mg/kg, i.p.) (A) Coronal sections were stained with ZIKV antiserum (green, left panel) and ZIKV+ cells were quantified (right panel). Virus+25HC: n = 9; Virus+Vehicle: n = 10. (B) ZIKV genomic RNA copies were measured by qRT-PCR, n = 3. (C) Similar positions of coronal sections were Nissl-stained, scale bars, 1mm. (D) Nissl staining was shown for the ZIKV-infected cortices with or without 25HC treatment (left). The thickness of different layers was measured (right), n = 20 for each group. MZ: marginal zone; CP: cortical plate; SP: sub-plate; IZ: intermediate zone; SVZ: sub-ventricle zone; VZ: ventricle zone. (E) Cortices were stained for Tbr1 (early born post-mitotic neuron marker, red) and NeuN (general post-mitotic neuron marker, white) (left). The thickness of the layers with individual markers was stained. Mock+Vehicle: n = 14 (Tbr1+), 8 (NeuN+); Mock+25HC: n = 15 (Tbr1+), 12 (NeuN+); Virus+Vehicle: n = 15 (Tbr1+), 11 (NeuN+); Virus+25HC: n = 12 (Tbr1+), 11 (NeuN+). (F) Cortices were stained with Phospho-Histone H3 (red, left). Relative P-H3+ cells in the cortex were quantified (right). (G) Cortices were stained with the activated form of caspase3 (red) and DAPI (blue) (left), caspase3+ cells were quantified (right). Data of (A), (B), and (D)–(G) are shown as means ± SEM from three independent experiments, ∗p ≤ 0.05, ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001, ∗∗∗∗p ≤ 0.0001, unpaired Student’s t test. Scale bars for (A) and (D)–(G): 100 μm. Immunity 2017 46, 446-456DOI: (10.1016/j.immuni.2017.02.012) Copyright © 2017 Terms and Conditions